Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

Evolution of biotechnological advances and regenerative therapies for endometrial disorders: a systematic review

Rodríguez-Eguren A., Bueno-Fernandez C., Gómez-Álvarez M., Francés-Herrero E., Pellicer A., Bellver J.

Systematic Review on Scar, published in Hum Reprod Update (2024) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Hum Reprod Update (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38796750
PMCID
PMC11369227
DOI
10.1093/humupd/dmae013
Citations
63

Abstract (original English)

Background The establishment and maintenance of pregnancy depend on endometrial competence. Asherman syndrome (AS) and intrauterine adhesions (IUA), or endometrial atrophy (EA) and thin endometrium (TE), can either originate autonomously or arise as a result from conditions (i.e. endometritis or congenital hypoplasia), or medical interventions (e.g. surgeries, hormonal therapies, uterine curettage or radiotherapy). Affected patients may present an altered or inadequate endometrial lining that hinders embryo implantation and increases the risk of poor pregnancy outcomes and miscarriage. In humans, AS/IUA and EA/TE are mainly treated with surgeries or pharmacotherapy, however the reported efficacy of these therapeutic approaches remains unclear. Thus, novel regenerative techniques utilizing stem cells, growth factors, or tissue engineering have emerged to improve reproductive outcomes. Objective and rationale This review comprehensively summarizes the methodologies and outcomes of emerging biotechnologies (cellular, acellular, and bioengineering approaches) to treat human endometrial pathologies. Regenerative therapies derived from human tissues or blood which were studied in preclinical models (in vitro and in vivo) and clinical trials are discussed. Search methods A systematic search of full-text articles available in PubMed and Embase was conducted to identify original peer-re

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
EndometriumHumansGynatresiaUterine DiseasesStem Cell TransplantationTissue EngineeringBiotechnologyRegenerative MedicinePregnancyFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research